| dc.description.abstract | Multiple sclerosis (MS) is a disease that affects the brain
and spinal cord, resulting in a variety of symptoms such
as vision, arm or leg movement, sensation, and balance
disorders.
Depletion of CD20+ B cells has been shown to be a
highly effective method of suppressing inflammatory
activity in MS patients. Anti-CD20 monoclonal
antibodies (mAbs) such as rituximab, ocrelizumab, and
ofatumumab have been developed for MS treatment.
CD20 is a cell-surface molecule expressed on most B cell subsets, including pre-B cells, immature, mature, and
memory B cells. CD20 is not, however, expressed on
pro-B cells, or on plasmablasts and plasma cells.
patients treated with rituximab and ocrelizumab do not
develop rebound inflammation following B-cell
reconstitution
Vaccination is an easy, safe, and efficient technique to
protect people from dangerous diseases before they
become infected. | en_US |
